Same gel. Same dose. Same 24 hours. Two very different outcomes.
A sneak peek at our results!

The chart shows one of our prototype formulations at a single concentration, run against two organisms side by side:
→ Gardnerella vaginalis, the main driver of bacterial vaginosis: below detection within 4 hours and still undetectable at 24.
→ Lactobacillus crispatus, the species most associated with a stable, healthy vaginal microbiome: a temporary dip, then full recovery to normal levels by 24 hours.
That is the whole idea behind Avodes. The problem with the current standard of care isn’t that it fails to kill — it’s that it doesn’t choose. In a 12-month cohort, 58% of women had BV again after standard metronidazole (Bradshaw et al., J Infect Dis, 2006), and roughly 1 in 4 women report vulvovaginitis after a course of antibiotics (Pirotta et al., MJA, 2003). Clear the protectors along with the pathogens and the loop restarts.
We’re developing a non-antibiotic topical formulation designed to break that loop — selective against BV-associated pathogens, including L. iners, while sparing L. crispatus. This is in-vitro data an at pre-clinical stage.
Yes, we have a mixed spp. BV biofilm testing results, they will be published in a research publication.


